Joel Neal, MD, PhD
![](https://education.binayfoundation.org/sites/default/files/styles/faculty_photo/public/faculty/2023-06/JWN_Headshot-Whitecoat_0.jpeg?itok=jk1QSYAu)
Dr. Joel Neal, MD, PhD, Associate Professor of Medicine (Oncology), maintains an active thoracic medical oncology practice, designs and conducts clinical trials, and facilitates translational research collaborations. His clinical trials expertise includes overcoming acquired resistance to targeted therapies, understanding and improving the efficacy of immunotherapy, and applying circulating tumor DNA technology to inform treatment decisions. He has published dozens of articles in the field of thoracic oncology, including in Lancet Oncology, Nature Medicine, and the Journal of Clinical Oncology. He leads the Stanford Thoracic Clinical Research Group and improves the Stanford cancer clinical research enterprise as medical director of the Cancer Clinical Trials Office. As IT Medical Director of the Stanford Cancer Center, he maintains and enhances the EPIC electronic health record to benefit providers and patients, and effects change through the NCCN EHR Oncology Advisory Group. He serves as study chair and thoracic core committee member in the ECOG-ACRIN cooperative group, is an active participant within the American Society of Clinical Oncology (ASCO) and contributes to the CME and Education committees within the International Association of the Study of Lung Cancer (IALSC). He has presented worldwide to educate clinicians and researchers.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:AstraZenecaTopic:advisory/consultingDate added:06/13/2023Date updated:03/14/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Genentech/RocheTopic:advisory/consulting, research fundingDate added:06/13/2023Date updated:03/14/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:ExelixisTopic:advisory/consulting, research fundingDate added:06/13/2023Date updated:03/14/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Takeda PharmaceuticalsTopic:advisory/consulting, research fundingDate added:06/13/2023Date updated:03/14/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Eli Lilly and CompanyTopic:advisory/consultingDate added:06/13/2023Date updated:03/14/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:AmgenTopic:advisory/consultingDate added:06/13/2023Date updated:03/14/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Iovance BiotherapeuticsTopic:advisory/consultingDate added:06/13/2023Date updated:03/14/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Blueprint PharmaceuticalsTopic:advisory/consultingDate added:06/13/2023Date updated:03/14/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Regeneron PharmaceuticalsTopic:advisory/consultingDate added:06/13/2023Date updated:03/14/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:NateraTopic:advisory/consultingDate added:06/13/2023Date updated:03/14/2024